Treats hypertension. ANDA 214489, held by Lupin. Azilsartan Kamedoxomil.
As of Nov 16, 2026, ANDA 214489 (Azilsartan Medoxomil), held by Lupin, was first approved by FDA on Jul 20, 2022, with 1 approved supplement and 0 published complete response letters.
Azilsartan medoxomil tablets are indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with azilsartan medoxomil tablets.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 20, 2022 | Original application | Approved |
| Azilsartan MedoxomilEQ 40MG MEDOXOMIL · tablet;oral | Azilsartan Kamedoxomil | Rx |
| Azilsartan MedoxomilEQ 80MG MEDOXOMIL · tablet;oral | Azilsartan Kamedoxomil | Rx |
| Jul 18, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jul 20, 2022 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters